Hermetica Superfood Encyclopedia
The Short Answer
Zerumbone, a monocyclic sesquiterpene ketone comprising 35.5–84.8% of the rhizome essential oil, drives the pharmacological activity of Layalaya by suppressing NF-κB signaling, inhibiting mast cell degranulation, and blocking platelet aggregation at concentrations of 100 μg/mL. Preclinical studies demonstrate that oral zerumbone at 0.1–10 mg/kg dose-dependently reduces airway hyperresponsiveness and inflammatory cytokine secretion in murine asthma models, and ethanolic extracts achieve 59.1% inhibition of β-hexosaminidase release in RBL-2H3 cells at 100 μg/mL, indicating potent anti-allergic activity.
CategoryRoot
GroupPacific Islands
Evidence LevelPreliminary
Primary KeywordLayalaya Zingiber zerumbet benefits
Layalaya — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
Zerumbone suppresses NF-κB transcriptional activity and reduces the release of pro-inflammatory cytokines, with oral doses of 0.1–10 mg/kg demonstrating reduced airway inflammation and cellular infiltration in BALB/c mouse asthma models.
**Anti-Allergic and Mast Cell Stabilization**
Ethanolic extracts inhibit β-hexosaminidase release from RBL-2H3 sensitized mast cells by 8.4–59.1% at 10–100 μg/mL, with the terpene linalool also contributing inhibitory activity at 100 μg/mL, suggesting a clinically relevant mast-cell-stabilizing mechanism.
**Antiplatelet and Cardiovascular Protection**
Zerumbone at 100 μg/mL achieves 100% inhibition of arachidonic-acid-induced platelet aggregation and 68% inhibition of collagen-induced aggregation in vitro, indicating potential benefit for thrombotic risk reduction.
**Immunomodulatory Effects**
An 80% ethanolic rhizome extract administered orally at 100–400 mg/kg for 15 days to male Wistar rats dose-dependently reduced neutrophil phagocytosis, directional migration, CD11b/CD18 integrin surface expression, and reactive oxygen species production, reflecting broad innate immune regulation.
**Antioxidant Protection**
The essential oil constituents, particularly zerumbone, humulene, and β-caryophyllene, contribute to free radical scavenging activity, with extract IC50 values reported at 91 μg/mL (ethanolic) and 68.2 μg/mL (aqueous) in cellular assay systems, indicating moderate to strong antioxidant capacity.
**Antidiabetic Potential**
Phytochemical profiling and in vitro assay data suggest that Zingiber zerumbet extracts modulate glycemic pathways, consistent with the broader Zingiberaceae pharmacological profile, though specific mechanistic data for this species remains under active investigation.
**Antimicrobial and Antiviral Activity**
Essential oils and solvent extracts of Z. zerumbet rhizomes display activity against a range of bacterial and fungal pathogens in vitro, attributed to the cytotoxic and membrane-disrupting properties of zerumbone and associated sesquiterpenes including humulene and β-caryophyllene.
Origin & History
Natural habitat
Zingiber zerumbet is native to South and Southeast Asia, with naturalized populations distributed across the Pacific Islands, including Fiji, Hawaii, and Polynesia, where it holds ethnomedicinal significance. It thrives in moist, tropical and subtropical environments at low to mid elevations, typically growing in forest margins, disturbed areas, and alongside cultivated land under partial shade with rich, well-drained soils. The rhizome, which accumulates the highest concentrations of bioactive essential oils, is the primary harvested organ and serves as the foundation for both traditional preparations and modern phytochemical investigation.
“Zingiber zerumbet has been integrated into the traditional healing systems of Pacific Island cultures, including Fiji, Hawaii, and Polynesia, where the rhizome has been employed for generations as a remedy for pain, inflammation, gastrointestinal complaints, and febrile illnesses, often administered as a decoction or topical preparation. In Fijian ethnomedicine, the plant is known as Layalaya and holds recognized status as a medicinal herb used in community healing practices, reflecting its deep cultural entrenchment across the Pacific region. In South and Southeast Asia, from which the plant originates, it is similarly documented in Ayurvedic and folk medical traditions under names such as 'shampoo ginger' or 'bitter ginger,' where both the rhizome and the milky fluid expressed from the mature inflorescence have been used medicinally and cosmetically. The common name 'shampoo ginger' in Hawaiian and broader Pacific use derives from the soapy, lather-producing juice of the immature cone-shaped inflorescence, which has been traditionally applied to condition and cleanse hair, illustrating the plant's dual role in medicinal and cosmetic ethnobotany.”Traditional Medicine
Scientific Research
The current evidence base for Layalaya (Zingiber zerumbet) consists exclusively of in vitro cell-based assays and in vivo animal studies, with no published human randomized controlled trials identified in available literature as of the time of this entry. Preclinical in vivo studies include oral administration of zerumbone (0.1–10 mg/kg) to BALB/c mice in an ovalbumin-sensitized asthma model with unspecified group sizes, demonstrating statistically significant reductions in airway hyperresponsiveness and cytokine levels, and an oral immunomodulation study in male Wistar rats using 80% ethanolic extract (100–400 mg/kg, 15 days) showing dose-dependent suppression of neutrophil phagocytosis and ROS. In vitro antiplatelet studies utilized zerumbone at 100 μg/mL against arachidonic acid, ADP, and collagen inducers with aspirin (25 μg/mL) as a positive control, and anti-allergic studies measured β-hexosaminidase inhibition in RBL-2H3 cells with IC50 values of 91 μg/mL (ethanolic) and 68.2 μg/mL (aqueous). The overall evidence is rated preliminary; while mechanistic signals are biologically plausible and internally consistent, the absence of clinical trials, standardized dosing protocols, and formal pharmacokinetic data in humans substantially limits translational confidence.
Preparation & Dosage
Traditional preparation
**Rhizome Essential Oil (Hydrodistillation)**
No standardized human dose established; research-grade preparations are standardized to ≥80% zerumbone content in the rhizome fraction; used topically or in aromatherapy contexts in traditional settings.
**Supercritical CO2 Extract**
Yields high-purity zerumbone-enriched fractions; no human dose established; superior terpene preservation compared to hydrodistillation.
**80% Ethanolic Rhizome Extract**
100–400 mg/kg in rats (15-day oral administration); human equivalent dose extrapolation is approximately 16–65 mg/kg using allometric scaling, though this has not been validated clinically
Preclinical immunomodulatory dose range was .
**Aqueous Rhizome Extract**
IC50 of 68.2 μg/mL for β-hexosaminidase inhibition in vitro; traditional decoctions and infusions of fresh or dried rhizome represent the primary ethnomedicinal form in Fijian and Pacific Island practice.
**Isolated Zerumbone (Oral)**
10 mg/kg corresponds to a human equivalent of approximately 0
Preclinical mouse dose of .81 mg/kg by FDA allometric conversion; no clinical dose or standardized supplement formulation currently available.
**Traditional Fijian Preparation**
Fresh rhizome is typically crushed, decocted, or applied as a poultice; timing and dosing are empirically guided by practitioner knowledge rather than standardized protocols.
Nutritional Profile
The primary nutritional and phytochemical value of Layalaya resides in its rhizome essential oil fraction rather than conventional macronutrient or micronutrient content, which has not been extensively characterized relative to edible ginger species. The essential oil is dominated by zerumbone (35.5–84.8% of total oil by GC analysis), with secondary sesquiterpenes including α-humulene (10.03–17.23%) and β-caryophyllene (6.9–10.2%), and monoterpenes including α-pinene and β-pinene (combined 10.3–31.4%), camphene (14.29–16.3%), sabinene (14.6%), and linalool (7.7–17.1%). Additional identified constituents include Δ3-carene, camphor, ar-curcumene, humulene oxide, α-terpineol, citral (up to 26.1% in certain chemotypes), limonene (0.8–1.3%), borneol (4.78%), and zingiberene (7.2%), with chemotype and geographic origin influencing relative proportions. Bioavailability of zerumbone and associated terpenes from oral preparations has not been formally quantified in human pharmacokinetic studies; lipophilicity of sesquiterpenes suggests absorption may be enhanced by co-administration with dietary fats or lipid-based delivery systems.
How It Works
Mechanism of Action
Zerumbone, the dominant sesquiterpene ketone in Z. zerumbet rhizome essential oil, exerts its primary anti-inflammatory effects through inhibition of the NF-κB signaling pathway, reducing downstream transcription of pro-inflammatory cytokines including IL-4, IL-5, and TNF-α, which collectively attenuate eosinophilic airway inflammation and bronchial hyperresponsiveness in preclinical asthma models. The compound also stabilizes mast cells by blocking IgE-mediated degranulation, as evidenced by suppression of β-hexosaminidase release—a surrogate marker for histamine and eicosanoid secretion—in RBL-2H3 cells, with linalool providing a complementary inhibitory contribution at 100 μg/mL. In the vascular compartment, zerumbone inhibits arachidonic acid metabolism and thromboxane-mediated pathways to achieve dose-dependent platelet aggregation inhibition, and the ethanolic extract modulates neutrophil effector functions by downregulating CD11b/CD18 (Mac-1) integrin expression, thereby reducing adhesion, transendothelial migration, and NADPH oxidase-dependent ROS generation. These converging mechanisms—NF-κB suppression, mast cell stabilization, integrin downregulation, and arachidonate pathway interference—explain the pleiotropic anti-inflammatory and immunomodulatory phenotype observed across multiple preclinical models.
Clinical Evidence
No human clinical trials investigating Layalaya (Zingiber zerumbet) or isolated zerumbone in defined patient populations have been reported in the peer-reviewed sources available for this entry, rendering a formal clinical efficacy summary impossible. Available preclinical data provides proof-of-concept for anti-inflammatory, anti-allergic, antiplatelet, and immunomodulatory effects, with the most quantitatively robust outcomes derived from murine asthma models and rat neutrophil suppression studies, though sample sizes were not specified in primary sources. Effect sizes from in vitro assays—such as 100% platelet aggregation inhibition at 100 μg/mL zerumbone and up to 59.1% β-hexosaminidase suppression—are pharmacologically meaningful but cannot be directly extrapolated to human therapeutic doses without bioavailability and pharmacokinetic characterization. Until adequately powered, placebo-controlled human trials are conducted, clinical confidence in specific therapeutic indications remains low despite promising preclinical signals.
Safety & Interactions
The safety profile of Layalaya is inadequately characterized for human use, as formal toxicology studies, maximum tolerated dose determinations, and multi-dose human safety trials have not been reported in available literature. In preclinical settings, oral zerumbone at 10 mg/kg in mice and 80% ethanolic extract at up to 400 mg/kg in rats for 15 days produced no reported overt toxicity, but the immunosuppressive reduction of neutrophil phagocytosis and ROS observed in the rat study raises a theoretical concern for impaired innate immune defense at higher doses or with prolonged use. The potent in vitro antiplatelet activity of zerumbone—achieving 100% inhibition of arachidonic-acid-induced aggregation at 100 μg/mL—suggests a clinically meaningful drug interaction risk with anticoagulant and antiplatelet agents (e.g., warfarin, aspirin, clopidogrel, NSAIDs), and caution is warranted pending clinical pharmacokinetic data. No data are available regarding safety during pregnancy or lactation, and given the pharmacological activity and traditional classification of related Zingiber species as uterotonic agents, use during pregnancy should be avoided until adequate safety evidence is established.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Zingiber zerumbet (L.) Sm.Shampoo gingerBitter gingerWild gingerAwapuhi kuahiwi
Frequently Asked Questions
What is zerumbone and why is it the key compound in Layalaya?
Zerumbone is a monocyclic sesquiterpene ketone that constitutes 35.5–84.8% of the rhizome essential oil of Zingiber zerumbet, making it the dominant and most pharmacologically characterized bioactive constituent in Layalaya. It mediates anti-inflammatory effects primarily through NF-κB pathway suppression, inhibits mast cell degranulation, blocks platelet aggregation at 100 μg/mL in vitro, and modulates neutrophil immune function in animal models, accounting for the majority of the plant's documented pharmacological activities.
Are there any human clinical trials supporting Layalaya's health benefits?
No human clinical trials for Layalaya (Zingiber zerumbet) or isolated zerumbone have been reported in the peer-reviewed literature available at the time of this entry, meaning all documented health benefits are based on preclinical in vitro cell assays and in vivo animal studies. While these preclinical results are pharmacologically promising—including reductions in asthma severity in mice and neutrophil suppression in rats—they cannot be directly translated to human efficacy or dosing recommendations without controlled clinical investigation.
What is the traditional use of Layalaya in Fijian medicine?
In Fijian ethnomedicine, Layalaya (Zingiber zerumbet) is a recognized medicinal plant used traditionally for its anti-inflammatory and analgesic properties, with the rhizome prepared as decoctions or poultices to address pain, inflammation, and related ailments. The plant is also used across the broader Pacific Island region for gastrointestinal complaints and febrile conditions, and its milky inflorescence juice has a well-documented traditional application as a hair and scalp treatment, which gave rise to the common name 'shampoo ginger' in Hawaiian culture.
Is Layalaya safe to take with blood thinners or anticoagulants?
Caution is warranted when combining Layalaya preparations with anticoagulant or antiplatelet drugs such as warfarin, aspirin, clopidogrel, or NSAIDs, because zerumbone achieves 100% inhibition of arachidonic-acid-induced platelet aggregation at 100 μg/mL in vitro, suggesting a potentially additive or synergistic bleeding risk. This interaction has not been evaluated in human pharmacokinetic or pharmacodynamic studies, and until clinical data are available, individuals on anticoagulant therapy should consult a qualified healthcare provider before using concentrated Z. zerumbet extracts or essential oils.
What dose of Layalaya or zerumbone has been studied in preclinical research?
Preclinical dosing studies have examined zerumbone at 0.1–10 mg/kg orally in BALB/c mice for anti-asthmatic effects, and an 80% ethanolic rhizome extract at 100–400 mg/kg orally for 15 days in male Wistar rats for immunomodulatory effects. Using standard FDA allometric scaling, a 10 mg/kg mouse dose approximates a human equivalent dose of roughly 0.81 mg/kg, but no standardized human supplement dose has been established, and these preclinical values should not be self-administered without clinical validation and pharmacokinetic confirmation.
How does Layalaya compare to other ginger species for anti-inflammatory benefits?
While common ginger (Zingiber officinale) contains gingerols and shogaols, Layalaya (Zingiber zerumbet) is distinguished by its unique zerumbone compound, which demonstrates more potent NF-κB suppression in preclinical models. Zerumbone's mechanism of reducing pro-inflammatory cytokine release appears more direct than the indirect pathways of common ginger constituents, making Layalaya potentially more effective for airway and allergic inflammation specifically.
What is the most effective form of Layalaya for mast cell stabilization and allergy support?
Ethanolic extracts of Layalaya have shown the strongest mast cell stabilization activity in research, inhibiting β-hexosaminidase release from sensitized mast cells more effectively than aqueous preparations. This suggests that alcohol-based extracts or tinctures may deliver superior bioavailability of zerumbone and related compounds compared to dried powder or decoctions.
Who should consider Layalaya supplementation based on current research findings?
Individuals with allergic inflammation, mast cell activation symptoms, or mild asthma may benefit most from Layalaya supplementation, given preclinical evidence showing reduced airway inflammation and cellular infiltration in asthma models. Those with chronic inflammatory conditions may also be good candidates, though human clinical data remains limited and supplementation should complement, not replace, medical treatment.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w layalaya-zingiber-zerumbet curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
